aibioVistagen faces securities class action and two derivative suits over PALISADE-3 trial statements
Tickers VTGN
A Northern District of California class action names Vistagen, CEO Shawn Singh and COO Joshua Prince. Two derivative suits are stayed behind it, and a separate pro se case was dismissed with prejudice on August 12.
Key facts
- Company
- Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
- News type
- Legal
- Primary source
- Vistagen Therapeutics 10-Q for the quarter ended June 30, 2026 (SEC EDGAR)
Vistagen Therapeutics (Nasdaq: VTGN) is defending a putative securities class action in the U.S. District Court for the Northern District of California, according to its 10-Q filed August 14, 2026. Stockholder Dan Eller filed Eller v. Vistagen Therapeutics, Inc. et al. (Case No. 3:26-cv-00427) on January 15, 2026. The complaint names the company, Shawn Singh and Joshua Prince.
Two stockholder derivative actions, Do v. Singh et al. (Case No. 4:26-cv-02656) and Strekal v. Singh et al. (Case No. 3:26-cv-04480), name Vistagen as nominal defendant and "certain of the Company's current and former officers and directors". They were filed in the same court on March 26 and May 13, 2026. The 10-Q does not name the individual derivative defendants. A separate pro se derivative suit in Nevada names the company and certain current and former board members, executive officers, employees and an advisor.
The case
The class action complaint alleges that the defendants "disseminated false and misleading statements and/or concealed material adverse facts" about the PALISADE-3 Phase 3 clinical trial. It asserts claims under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. The court appointed Eric Weinberger as lead plaintiff on April 16, 2026. On June 16, 2026 he filed an amended complaint on behalf of a putative class of stockholders who acquired Vistagen securities between April 1, 2024 and December 16, 2025, both dates inclusive. It seeks unspecified damages.
The derivative complaints rest on allegations the 10-Q describes as primarily the same as those in the class action. All of this is allegation. Vistagen says the class action claims are "wholly without merit" and that it intends to defend them vigorously.
Defendants
In the class action, the 10-Q names three defendants: Vistagen, Shawn Singh and Joshua Prince. Vistagen's 10-K filed June 15, 2026 lists Singh as president, chief executive officer and a director, and says Prince has been chief operating officer since October 2023.
For the derivative suits, the 10-Q gives only that general description. Vistagen's board according to that 10-K, which is the filing nearest in time to the March and May 2026 complaints, was Singh, Jon S. Saxe (chair), Ann M. Cunningham, Joanne Curley and Margaret M. FitzPatrick. No filing we read states that any of these people is a derivative defendant.
Where it stands
Vistagen's response to the amended class action complaint was due August 18, 2026. The court granted motions to relate the two derivative actions to the class action on July 2 and July 13, 2026. A stipulation to consolidate them and stay the consolidated action pending resolution of the class action was filed on July 13, and the court granted it on July 30, 2026.
The 10-Q gives no loss estimate for these cases and does not describe insurance or indemnification. It adds that more lawsuits may follow and that Vistagen will not necessarily announce further similar complaints.
Related matters
Cesario et al. v. Vistagen Therapeutics, Inc. et al. (Case No. 4:25-cv-01510) was filed pro se on February 13, 2025 by John Cesario and David Preka against the company, its board, certain executive officers, professional services and financial advisors, and industry analysts. On June 15, 2026 the plaintiffs moved to dismiss the unserved defendants, leaving the company and Saxe. At a July 14 hearing they moved orally to dismiss Saxe without prejudice. On August 12, 2026 the court dismissed the action with prejudice, according to the 10-Q.
The same plaintiffs filed the Nevada derivative action (Case No. 2:26-cv-01128) on April 10, 2026. On July 29, 2026 Vistagen asked the court to require the Cesario plaintiffs to post a $100,000 bond under Nevada Revised Statutes section 41.520.
Why it matters to shareholders
The 10-Q says litigation is costly, may divert management's attention and, if Vistagen did not prevail, could adversely affect its business, results of operations, liquidity and financial condition. The same filing reports cash, cash equivalents and marketable securities of $31.7 million at June 30, 2026 and says management concluded that substantial doubt exists about its ability to continue as a going concern. Nasdaq gave Vistagen until February 1, 2027 to regain compliance with the $1.00 minimum bid price rule.